(Sharecast News) - Biogen said on Wednesday that it has agreed to buy Human Immunology Biosciences (HI-Bio) for up to $1.8bn.
HI-Bio is a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).

Biogen has agreed to pay $1.15bn upfront and up to $650m...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE